FDA Approves Talzenna for Metastatic Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Approval of Talzenna was granted to Pfizer.
